Literature DB >> 22083671

Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells.

Oshrat Attar-Schneider1, Liat Drucker, Victoria Zismanov, Shelly Tartakover-Matalon, Gloria Rashid, Michael Lishner.   

Abstract

Multiple myeloma (MM), a malignancy of plasma cells, remains fatal despite introduction of novel therapies, partially due to humoral factors, including vascular endothelial growth factor (VEGF), in their microenvironment. The aim of this study was to explore the efficacy of anti-VEGF treatment with bevacizumab directly on MM cells. Particular attention was directed to the affect of VEGF inhibition on protein translation initiation. Experiments were conducted on MM cells (lines, bone marrow (BM) samples) cultured on plastic. Inhibition of VEGF was achieved with the clinically employed anti-VEGF antibody, bevacizumab, as a platform and its consequences on viability, proliferation, and survival was assessed. VEGF downstream signals of established importance to MM cell biology were assayed as well, with particular emphasis on translation initiation factor eIF4E. We showed that blocking VEGF is deleterious to the MM cells and causes cytostasis. This was evidenced in MM cell lines, as well as in primary BM samples (BM MM). A common bevacizumab-induced attenuation of critical signaling effectors was determined: VEGFR1, mTOR, c-Myc, Akt, STAT3, (cell lines) and eIF4E translation initiation factor (lines and BM). ERK1/2 displayed a variegated response to bevacizumab (lines). Utilizing a constitutively Akt-expressing MM model, we showed that the effect of bevacizumab on viability and eIF4E status is Akt-dependent. Of note, the effect of bevacizumab was achieved with high concentrations (2 mg/ml), but was shown to be specific. These findings demonstrate that bevacizumab has a direct influence on major pathways critically activated in MM that is independent from its established effect on angiogenesis. The cytostatic effect of VEGF inhibition on MM cells underscores its potential in combined therapy, and our findings, regarding its influence on translation initiation, suggest that drugs that unbalance cellular proteostasis may be particularly effective.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083671     DOI: 10.1038/labinvest.2011.162

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  12 in total

1.  Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation.

Authors:  Oshrat Attar-Schneider; Victoria Zismanov; Liat Drucker; Maya Gottfried
Journal:  Tumour Biol       Date:  2015-10-30

2.  Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.

Authors:  Andreas Günther; Philipp Baumann; Renate Burger; Christian Kellner; Wolfram Klapper; Ralf Schmidmaier; Martin Gramatzki
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

3.  Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.

Authors:  M Koldehoff; D W Beelen; A H Elmaagacli
Journal:  Cancer Gene Ther       Date:  2014-06-06       Impact factor: 5.987

4.  Discovering discovery patterns with Predication-based Semantic Indexing.

Authors:  Trevor Cohen; Dominic Widdows; Roger W Schvaneveldt; Peter Davies; Thomas C Rindflesch
Journal:  J Biomed Inform       Date:  2012-07-26       Impact factor: 6.317

5.  Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI.

Authors:  Oshrat Attar-Schneider; Liat Drucker; Maya Gottfried
Journal:  Lab Invest       Date:  2016-08-08       Impact factor: 5.662

6.  Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma.

Authors:  Lee Campbell; Bharat Jasani; David Fr Griffiths; Mark Gumbleton
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

7.  CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.

Authors:  Abdel Kareem Azab; Ilyas Sahin; Michele Moschetta; Yuji Mishima; Nicholas Burwick; Johann Zimmermann; Barbara Romagnoli; Kalpana Patel; Eric Chevalier; Aldo M Roccaro; Irene M Ghobria
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

8.  eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling.

Authors:  Oshrat Attar-Schneider; Metsada Pasmanik-Chor; Shelly Tartakover-Matalon; Liat Drucker; Michael Lishner
Journal:  Oncotarget       Date:  2015-02-28

9.  Silica nanoparticles enhance autophagic activity, disturb endothelial cell homeostasis and impair angiogenesis.

Authors:  Junchao Duan; Yongbo Yu; Yang Yu; Yang Li; Peili Huang; Xianqing Zhou; Shuangqing Peng; Zhiwei Sun
Journal:  Part Fibre Toxicol       Date:  2014-09-30       Impact factor: 9.400

Review 10.  Bisphosphonates for delivering drugs to bone.

Authors:  Shuting Sun; Jianguo Tao; Parish P Sedghizadeh; Philip Cherian; Adam F Junka; Esmat Sodagar; Lianping Xing; Robert K Boeckman; Venkatesan Srinivasan; Zhenqiang Yao; Brendan F Boyce; Brea Lipe; Jeffrey D Neighbors; R Graham G Russell; Charles E McKenna; Frank H Ebetino
Journal:  Br J Pharmacol       Date:  2021-04-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.